Bnp Paribas Asset Management Holding S.A. Janux Therapeutics, Inc. Transaction History
Bnp Paribas Asset Management Holding S.A.
- $41 Billion
- Q2 2025
A detailed history of Bnp Paribas Asset Management Holding S.A. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Bnp Paribas Asset Management Holding S.A. holds 371 shares of JANX stock, worth $8,904. This represents 0.0% of its overall portfolio holdings.
Number of Shares
371Holding current value
$8,904% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
186Shares Held
55.9MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$269 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$107 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$70.1 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$60.6 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$56.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...